MobileODT is rolling out its Enhanced Visual Assessment (EVA) System in what it’s calling the first large-scale pilot program to examine the use of augmented intelligence (AI) for cervical cancer screenings.
Partnering with Apollo Hospitals and distributor Genworks, the women’s health imaging enterprise will conduct the study in India, where it will deploy its FDA-cleared, smart mobile colposcope for use in assessing women who lack access to lifesaving cervical exams.
“The AVE algorithm that will be reviewed in the pilot with Apollo Hospital in India was found to be more than 90 percent effective at detecting cancer,” MobileODT’s Yael Misrahi, head of global partnerships, and sales marketing manager Sara Vehling told HCB News. “The traditional, gold-standard Pap smear is only 68 percent effective. AVE also outperformed expert human examination.”
More than 432 million women in India risk developing cervical cancer. Only 3.1 percent, however, receive screening due to lack of available equipment and qualified colposcopists, and poor socioeconomic conditions. Of those positively diagnosed following HPV testing or a Pap smear, up to 80 percent do not seek treatment, despite it being a highly treatable form of cancer when detected early.